Tonea corporis treatment

Reading File

Finding Sources

Reading File

The Dermatology 5e block already contained the treatment section. Let me review the truncated output from earlier more carefully — the Red Book and Fitzpatrick's blocks already contain treatment info. I have enough to give a comprehensive answer.

Tinea Corporis — Treatment

Definition: Dermatophytosis of glabrous skin (trunk, extremities, face), excluding palms, soles, nails, and groin. The classic lesion is an annular ("ringworm") plaque with an advancing, scaly, erythematous, sometimes vesicular border and central clearing. — Fitzpatrick's Dermatology, Vol. 1–2

Topical Antifungals (First-line for localized disease)

Topical therapy is effective for most uncomplicated, localized cases. Treatment duration is typically 2–4 weeks (until clinical resolution plus 1 week beyond).

Agent	Class	Application
Terbinafine 1% cream/gel	Allylamine	Once or twice daily × 1–2 weeks
Clotrimazole 1% cream	Azole	Twice daily × 2–4 weeks
Miconazole 2% cream	Azole	Twice daily × 2–4 weeks
Econazole 1% cream	Azole	Once daily × 2–4 weeks
Ketoconazole 2% cream	Azole	Once daily × 2–4 weeks
Oxiconazole 1% cream	Azole	Once or twice daily
Naftifine 1% cream/gel	Allylamine	Once daily × 4 weeks
Butenafine 1% cream	Benzylamine	Once daily × 2–4 weeks
Ciclopirox 0.77% cream	Hydroxypyridinone	Twice daily
Tolnaftate 1%	Thiocarbamate	Twice daily

Allylamines (terbinafine, naftifine) and butenafine are generally fungicidal and may allow shorter courses than azoles (which are fungistatic). — Red Book 2021; Dermatology 5e

Apply to the lesion and extend 2 cm beyond the visible margin. Avoid corticosteroid-containing combination products — these can produce tinea incognito (masked, spreading infection with atypical morphology).

Oral Antifungals (Systemic therapy)

Indicated when:

Extensive or widespread disease
Lesions unresponsive to topical therapy
Majocchi granuloma (follicular/deep invasion — always requires systemic treatment)
Immunocompromised patient
Multiple or overlapping sites

Agent	Dose	Duration
Terbinafine	250 mg/day (adult)	2–4 weeks
Itraconazole	200 mg/day	1–2 weeks
Fluconazole	150–200 mg/week	4 weeks
Griseofulvin (microsize)	500 mg/day (adult); 10–20 mg/kg/day (children)	4–6 weeks

Terbinafine and itraconazole are preferred over griseofulvin due to shorter duration and higher efficacy. — Fitzpatrick's Dermatology; Red Book 2021

Special Situations

Tinea incognito (treated with topical steroids): Discontinue corticosteroids, confirm diagnosis with KOH prep or culture, treat with appropriate antifungal.

Majocchi granuloma: Oral terbinafine 250 mg/day for 4–12 weeks is first-line. Topical agents alone are inadequate because of deep follicular/dermal involvement.

Tinea corporis gladiatorum (wrestlers, contact sports — usually T. tonsurans): Oral terbinafine is preferred; affected athletes should be excluded from contact until treated.

Immunocompromised patients: May require prolonged oral therapy; lesions can be non-inflammatory (grouped papules/pustules without erythema).

Children: Terbinafine, griseofulvin, fluconazole, and itraconazole are used; topical azoles and allylamines are safe. Age restrictions vary by specific product (e.g., miconazole ≥2 years). — Red Book 2021

Ancillary Measures

Treat concurrent tinea pedis or tinea capitis to eliminate reservoirs of reinfection
Use loose-fitting, breathable clothing to reduce occlusion and moisture
Avoid sharing towels, clothing, or sports equipment
If tinea pedis coexists: apply socks before underwear to prevent autoinoculation — Fitzpatrick's Dermatology

Diagnosis Confirmation

When diagnosis is uncertain: KOH wet mount of skin scrapings from the scaly leading edge shows branching hyphae. Fungal culture on Sabouraud dextrose agar (2–4 weeks) identifies species. Wood's lamp examination is generally not fluorescent (most causative Trichophyton spp. do not fluoresce). — Red Book 2021

Hypothyroidism in pregnancy treatment

Reading File

Finding Sources

Reading File

Loading Image

Reading File

I now have comprehensive, authoritative content from Goodman & Gilman's, Tietz, and Katzung. I can provide a thorough answer.

Hypothyroidism in Pregnancy — Treatment

Why Treatment Matters

Untreated overt maternal hypothyroidism carries significant risks:

Maternal: miscarriage, preeclampsia, preterm delivery
Fetal/neonatal: neonatal mortality (from preterm delivery), low birth weight, impaired neurocognitive and motor development (early fetal brain development depends on maternal T4)

Subclinical hypothyroidism (SCH) carries the same risks but at lower frequency. — Tietz Textbook of Laboratory Medicine, 7th ed.; Goodman & Gilman's

Diagnosis in Pregnancy

Use trimester-specific TSH reference intervals (TSH rises slightly across trimesters)
Overt hypothyroidism: elevated TSH + low free T4
SCH: elevated TSH + normal free T4
TSH is the best test for evaluating thyroid status and monitoring response in pregnancy; standard free T4 analogue assays are less reliable in the 2nd and 3rd trimesters due to elevated TBG — Goodman & Gilman's

Who to Treat (ATA Recommendations)

Levothyroxine is indicated in all pregnant women with: — Tietz, 7th ed.

Condition	Recommendation
TSH above trimester-specific reference interval + low fT4	Treat
TSH > 10 mIU/L regardless of fT4	Treat
SCH + TPO antibody positive	Treat
SCH + TPO antibody negative	Evidence insufficient; monitoring preferred
Euthyroid + TPO antibody positive	Monitor (do not treat)
Isolated hypothyroidism (low fT4, normal TSH)	Do not treat

Treatment Agent

Levothyroxine (L-T4) is the drug of choice — it is safe for the fetus.

Dosing in Pregnancy

Levothyroxine requirements increase during pregnancy due to:

Elevated TBG (driven by estrogen) — more T4 bound, less free
Placental Dio3 expression (deiodinase that degrades T4)
Small transplacental transfer of T4 to the fetus

Practical approach:

Women already on levothyroxine: increase dose by ~25–30% as soon as pregnancy is confirmed — do not wait for TSH to rise
Practical method: take two extra tablets per week (on separate days) — this achieves approximately 30% dose increase without changing the daily tablet
Women newly diagnosed in pregnancy: start standard replacement and titrate to TSH target — Goodman & Gilman's; Katzung, 16th ed.

TSH targets (trimester-specific): — Katzung, 16th ed.

Trimester	TSH Target (mIU/L)
First	0.1 – 2.5
Second	0.2 – 3.0
Third	0.3 – 3.0

Monitoring Schedule

Timeframe	Frequency
First 20 weeks (dose adjustment period)	TSH every 4 weeks
26–32 weeks gestation	At least once
Women with SCH not initially treated	TSH + fT4 every 4 weeks until 16–20 weeks, then at 26–32 weeks

Administration Tips

Take levothyroxine on an empty stomach, 30–60 minutes before food
Separate from prenatal vitamins, calcium, and iron supplements by at least 4 hours — these reduce T4 absorption — Katzung, 16th ed.
The approximate 7-day plasma half-life of levothyroxine means it takes several weeks to reach a new steady state after any dose change — proactive early adjustment is critical — Goodman & Gilman's

Postpartum Management

Revert to pre-pregnancy dose the day after delivery
Recheck thyroid function tests 6 weeks postpartum — at this point, results are no longer influenced by pregnancy physiology — Tietz, 7th ed.; Goodman & Gilman's
Watch for postpartum thyroiditis in TPO antibody-positive women

Special Situation: Myxedema Crisis in Pregnancy

Use IV levothyroxine — safe for the fetus — Tintinalli's Emergency Medicine
Loading dose 200–400 µg IV, then daily maintenance (50–100 µg/day IV)
Some clinicians add liothyronine (T3) IV until patient is stable
Supportive care: ventilation, passive warming, hyponatremia correction, glucocorticoids (until adrenal insufficiency excluded) — Goodman & Gilman's

This is a shared conversation. Sign in to Orris to start your own chat.